Summary: New research shows that repeated ketamine exposure causes broad structural changes across the brain’s dopamine system, underscoring the need for more targeted ketamine therapies that limit unintended effects on other dopamine-regulated regions.
Researchers mapped ketamine’s effects throughout the mouse brain and found that sustained exposure reduces dopamine neurons in midbrain regions associated with mood regulation while increasing dopamine neurons in the hypothalamus, which controls metabolism and basic physiological functions. These region-specific changes help explain both ketamine’s therapeutic potential—particularly for mood and eating disorders—and some of the dissociative behavioral effects reported with repeated use.
The study supports a shift away from whole-brain ketamine dosing toward approaches that selectively target brain regions most relevant to the condition being treated. By narrowing where ketamine acts, clinicians may preserve therapeutic benefits while minimizing collateral changes to dopamine circuits that underlie other functions.
Key findings
- Repeated ketamine use produces widespread, region-specific structural alterations across the brain’s dopamine system.
- Targeted delivery of ketamine to specific brain regions could reduce unintended changes in unrelated dopamine circuits.
- Ketamine’s opposite effects on dopamine neurons in mood-related versus metabolism-related regions may underlie its clinical effects in mood disorders and its promise for treating certain eating disorders.
Source: Columbia University
Context and clinical relevance: Ketamine, long used as an anesthetic and sometimes encountered as a recreational drug, has in recent years been repurposed in medicine for a variety of uses. It serves as an alternative to opioids for pain control and is increasingly used to treat treatment-resistant depression. As its therapeutic use expands, understanding ketamine’s longer-term effects on brain circuitry is essential to maximizing benefits and limiting harms.
In work published in the journal Cell Reports, scientists in Columbia’s biology and biomedical engineering departments generated a whole-brain map of ketamine’s anatomical effects on dopamine neurons in mice. Their high-resolution approach allowed them to detect changes not only at the level of brain regions but down to sub-cellular structures, revealing how chronic exposure rewires dopamine connections across sensory and cognitive networks.
The investigators report that repeated daily ketamine exposure over a period of up to ten days produced statistically significant changes in dopamine circuitry detectable after ten days of treatment. These changes were observed at both a dose comparable to those used in mouse models of depression and at a higher, anesthesia-level dose, indicating that ketamine’s impact on dopamine networks is dose-spanning.
Specifically, dopamine neuron numbers decreased in midbrain areas implicated in mood regulation. Such reductions may help explain why chronic ketamine abuse can produce symptoms resembling mood disorders such as schizophrenia-spectrum disturbances. Conversely, ketamine raised dopamine neuron counts in the hypothalamus, which controls metabolic and homeostatic processes; this change provides a plausible mechanism for ketamine’s observed effects on appetite and its emerging use in treating certain eating disorders.
Beyond changes in neuron numbers, the study revealed altered dopamine axon densities across functional networks: reductions in sensory areas responsible for hearing and vision, alongside increases in axonal density within cognitive centers. These distributed shifts in dopamine wiring may underlie the dissociative and cognitive behavioral changes associated with repeated ketamine exposure.
“Instead of bathing the entire brain in ketamine, as most therapies now do, our whole-brain mapping data indicates that a safer approach would be to target specific parts of the brain with it, so as to minimize unintended effects on other dopamine regions of the brain,” said Raju Tomer, the senior author. Co-author Malika Datta added, “The restructuring of the brain’s dopamine system that we see after repeated ketamine use may be linked to cognitive behavioral changes over time.”
This work marks a technological advance in neuroimaging and neuroanatomy: it is the first study to map chronic ketamine-induced changes across the entire brain at sub-cellular resolution, rather than focusing on a single hypothesized region. According to co-author Yannan Chen, the methods chart “a new technological frontier” for comprehensive, high-resolution brain studies.
Columbia psychiatrist and neuroscientist Bradley Miller emphasized the clinical importance: “Ketamine rapidly resolves depression in many patients with treatment resistant depression, and it is being investigated for longer term use to prevent the relapse of depression. This study reveals how ketamine rewires the brain with repeated use. This is an essential step for developing targeted treatments that effectively treat depression without some of the unwanted side effects of ketamine.”
The research was supported by the National Institutes of Health (NIH) and the National Institute of Mental Health (NIMH). Lead authors Malika Datta and Yannan Chen conducted the work in Raju Tomer’s lab at Columbia; Datta is now a postdoctoral fellow at Yale.
Tomer concluded: “This study gives us a deeper brain-wide perspective of how ketamine functions that we hope will contribute to improved uses of this highly promising drug in various clinical settings as well as help minimize its recreational abuse. More broadly, the study demonstrates that the same type of neurons located in different brain regions can be affected differently by the same drug.”
About this neuroscience research news
Author: Christopher Shea
Source: Columbia University
Contact: Christopher Shea – Columbia University
Image: The image is credited to Neuroscience News
Original Research: The findings are published in Cell Reports